Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

171 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Enzalutamide for the treatment of nonmetastatic castration-resistant prostate cancer.
Altavilla A, Casadei C, Lolli C, Menna C, Ravaglia G, Gurioli G, Farolfi A, Brighi N, Conteduca V, Burgio SL, Schepisi G, Rossi L, Gargiulo S, Lisotti I, De Giorgi U. Altavilla A, et al. Among authors: farolfi a. Expert Opin Pharmacother. 2020 Dec;21(17):2091-2099. doi: 10.1080/14656566.2020.1803281. Epub 2020 Aug 12. Expert Opin Pharmacother. 2020. PMID: 32783772 Review.
Sorafenib for the treatment of breast cancer.
Bronte G, Andreis D, Bravaccini S, Maltoni R, Cecconetto L, Schirone A, Farolfi A, Fedeli A, Serra P, Donati C, Amadori D, Rocca A. Bronte G, et al. Among authors: farolfi a. Expert Opin Pharmacother. 2017 Apr;18(6):621-630. doi: 10.1080/14656566.2017.1309024. Epub 2017 Apr 7. Expert Opin Pharmacother. 2017. PMID: 28335647 Review.
Immunotherapy for Prostate Cancer: Where We Are Headed.
Schepisi G, Farolfi A, Conteduca V, Martignano F, De Lisi D, Ravaglia G, Rossi L, Menna C, Bellia SR, Barone D, Gunelli R, De Giorgi U. Schepisi G, et al. Among authors: farolfi a. Int J Mol Sci. 2017 Dec 5;18(12):2627. doi: 10.3390/ijms18122627. Int J Mol Sci. 2017. PMID: 29206214 Free PMC article. Review.
Inflammatory Indexes as Prognostic and Predictive Factors in Ovarian Cancer Treated with Chemotherapy Alone or Together with Bevacizumab. A Multicenter, Retrospective Analysis by the MITO Group (MITO 24).
Farolfi A, Petrone M, Scarpi E, Gallà V, Greco F, Casanova C, Longo L, Cormio G, Orditura M, Bologna A, Zavallone L, Ventriglia J, Franzese E, Loizzi V, Giardina D, Pigozzi E, Cioffi R, Pignata S, Giorda G, De Giorgi U. Farolfi A, et al. Target Oncol. 2018 Aug;13(4):469-479. doi: 10.1007/s11523-018-0574-1. Target Oncol. 2018. PMID: 29948780
Plasma androgen receptor and serum chromogranin A in advanced prostate cancer.
Conteduca V, Scarpi E, Salvi S, Casadio V, Lolli C, Gurioli G, Schepisi G, Wetterskog D, Farolfi A, Menna C, De Lisi D, Burgio SL, Beltran H, Attard G, De Giorgi U. Conteduca V, et al. Among authors: farolfi a. Sci Rep. 2018 Oct 18;8(1):15442. doi: 10.1038/s41598-018-33774-4. Sci Rep. 2018. PMID: 30337589 Free PMC article.
Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer.
Conteduca V, Gurioli G, Rossi L, Scarpi E, Lolli C, Schepisi G, Farolfi A, De Lisi D, Gallà V, Burgio SL, Menna C, Amadori A, Losi L, Amadori D, Costi MP, De Giorgi U. Conteduca V, et al. Among authors: farolfi a. BMC Cancer. 2018 Dec 19;18(1):1267. doi: 10.1186/s12885-018-5180-1. BMC Cancer. 2018. PMID: 30567527 Free PMC article.
171 results